Thrombin-JMI Related Published Studies
Well-designed clinical trials related to Thrombin-JMI (Thrombin Topical)
Discovery and clinical evaluation of
1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-ph
enylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine
P1 motif. [2010]
A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. [2009.04]
Efficacy and safety of topical application of human fibrinogen/thrombin-coated collagen patch (TachoComb) for treatment of air leakage after standard lobectomy. [2004.02]
Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. [2002.05]
Effect of topical and subcutaneous epinephrine in combination with topical thrombin in blood loss during immediate near-total burn wound excision in pediatric burned patients. [1999.09]
Wound hematoma: prophylaxis with topical thrombin. [1989.05]
Well-designed clinical trials possibly related to Thrombin-JMI (Thrombin Topical)
Effect of the carrier solution for hydroxyethyl starch on platelet aggregation
and clot formation. [2012]
Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a
randomized controlled trial. [2012]
A randomized, double blind, placebo and active comparator controlled pilot study
of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical
origin. [2012]
Thromboprophylaxis in patients older than 75 years or with moderate renal
impairment undergoing knee or hip replacement surgery [corrected]. [2012]
Anticoagulating obese patients in the modern era. [2011]
Impact of adjunctive cilostazol therapy on platelet function profiles in patients
with and without diabetes mellitus on aspirin and clopidogrel therapy. [2011]
Dabigatran vs. placebo in patients with acute coronary syndromes on dual
antiplatelet therapy: a randomized, double-blind, phase II trial. [2011]
Comparative validation of a novel risk score for predicting bleeding risk in
anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile
INR, Elderly, Drugs/Alcohol Concomitantly) score. [2011]
The effects of sheet-type absorbable topical collagen hemostat used to prevent pulmonary fistula after lung surgery. [2010.08]
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation
activity biomarkers following acute coronary syndrome. [2010]
Double-blind, placebo-controlled Phase II studies of the protease-activated
receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary
syndrome or high-risk coronary artery disease. [2010]
Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study. [2010]
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip
or knee arthroplasty: a pooled analysis of three trials. [2010]
A multicenter, phase III trial of hemocoagulase Agkistrodon: hemostasis,
coagulation, and safety in patients undergoing abdominal surgery. [2010]
Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. [2009.11]
Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. [2005.05]
Comparison of a new fibrin sealant with standard topical hemostatic agents. [2004.11]
Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy. [2004.11]
Hemostatic effect of Vivostat patient-derived fibrin sealant on split-thickness skin graft donor sites. [2003.04]
Inhibition of neurogenic inflammation by the Amazonian herbal medicine sangre de grado. [2001.09]
A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. [2001.08.01]
Efficacy and safety of topical hirudin (Hirudex): a double-blind, placebo-controlled study. [2001.03]
Autologous fibrin sealant reduces pain after tonsillectomy. [2001.02]
Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. [2000.05]
[Comparative thrombotic risk of two contrast agents in coronary angiography] [1994]
Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. [1989.02]
Other research related to Thrombin-JMI (Thrombin Topical)
The efficacy of a thrombin-based hemostatic agent in unilateral total knee
arthroplasty: a randomized controlled trial. [2012]
Eculizumab therapy results in rapid and sustained decreases in markers of
thrombin generation and inflammation in patients with PNH independent of its
effects on hemolysis and microparticle formation. [2012]
Oral factor Xa and direct thrombin inhibitors: a clinical perspective. [2012]
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next
Diadochian War? [2012]
Effects of antithrombin and gabexate mesilate on disseminated intravascular
coagulation: a preliminary study. [2012]
Prospective randomized evaluation of a collagen/thrombin and autologous platelet
hemostatic agent during total knee arthroplasty. [2012]
Immunogenicity and safety of re-exposure to recombinant human thrombin in surgical hemostasis. [2011.12]
Immune-mediated coagulopathy associated with topical bovine thrombin: review of the pediatric literature. [2011.03]
Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus. [2011.02]
[Expectation to and problems of thrombin inhibitor]. [Article in Japanese] [2011]
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis
of the Dabigatran versus Warfarin clinical trial. [2011]
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin
inhibitor. [2011]
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran
etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. [2011]
Efficacy and safety of closing postcatheterisation pseudoaneurysms with
ultrasound-guided thrombin injections using two approaches: bolus versus slow
injection. A prospective randomised trial. [2011]
Comparison of purified plant polysaccharide (HemoStase) versus gelatin-thrombin
matrix (FloSeal) in controlling bleeding during sinus surgery: a randomized
controlled trial. [2011]
Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin. [2010.12.01]
Persistence of antibodies to the topical hemostat bovine thrombin. [2010.12]
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. [2010.12]
Topical recombinant human thrombin in surgical hemostasis. [2010.07]
Acquired factor V deficiency associated with exposure to bovine thrombin in a burn patient. [2010.03]
Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. [2010.02]
Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System. [2010.02]
Enhancement of incisional wound healing by thrombin conjugated iron oxide nanoparticles. [2010.02]
Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. [2009.11.19]
A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. [2009.07]
Recent developments in topical thrombins. [2009.07]
Thrombin products: economic impact of immune-mediated coagulopathies and practical formulary considerations. [2009.07]
Topical thrombins: benefits and risks. [2009.07]
Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. [2009.05]
The use of thrombin in the radiology department. [2009.03]
Topical hemostasis: a valuable adjunct to control bleeding in the operating room, with a special focus on thrombin and fibrin sealants. [2009.02]
A gelatin-thrombin matrix for hemostasis after endoscopic sinus surgery. [2009.01]
Topical use of recombinant human thrombin for operative hemostasis. [2009.01]
A review of three stand-alone topical thrombins for surgical hemostasis. [2009.01]
Recombinant human thrombin: in surgical hemostasis. [2009]
Topical bovine thrombin and adverse events: a review of the literature. [2008.07]
Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. [2007.12]
A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. [2007.08]
Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. [2007.04]
Topical thrombin-related corneal calcification. [2006.09]
The clinical use and immunologic impact of thrombin in surgery. [2006.04]
Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. [2006.04]
Severe coagulopathy following intraoperative use of topical thrombin. [2004.05]
A review of the therapeutic uses of thrombin. [2004.05]
The combination of platelet-enriched autologous plasma with bovine collagen and thrombin decreases the need for multiple blood transfusions in trauma patients with retroperitoneal bleeding. [2004.01]
Hemostasis in endoscopic sinus surgery using a specific gelatin-thrombin based agent (FloSeal). [2003.12]
Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population. [2003.12]
Relative purity of thrombin-based hemostatic agents used in surgery. [2003.10]
Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis. [2003.08]
Use of endoscopic fibrinogen-thrombin in the treatment of severe hemoptysis. [2003.07]
Obliteration of femoral artery pseudoaneurysm by thrombin injection. [2002.10]
[Use of thrombin powder after tooth extraction in patients receiving anticoagulant therapy] [2002.07]
Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. [2002.06]
Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. [2002.02]
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis. [2001.12]
Exposure of mice to topical bovine thrombin induces systemic autoimmunity. [2001.11]
Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. [2001.10]
Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients. [2001.04]
Thrombin attenuation is neuroprotective in the injured rat optic nerve. [2001.02]
Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. [2001.01]
Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. [2000.11]
Ultrasound-guided thrombin injection of iatrogenic femoral pseudoaneurysms: a prospective analysis. [2000.10]
Antibodies to topical bovine thrombin correlate with access thrombosis. [2000.05]
Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin. [1997.09]
Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. [1997.02]
Thrombin-soaked gelatin sponge and brain edema in rats. [1996.08]
Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. [1996.05]
Comparison of topical fibrin glue, fibrinogen, and thrombin in preventing seroma formation in a rat model. [1995.03]
Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. [1994.08]
|
